Component
Human taxane-associated peripheral neuropathy severity
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
At 24 weeks in the same taxane trial, the acetyl-L-carnitine arm had worse neuropathy scores and more severe neurotoxicity than placebo.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Same randomized trial; prespecified secondary follow-up.
- limitations
- Not a demonstrated molecular explanation of the harm; keep the clinical outcome visible.
- nutrient_topic
- L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
- plain_language
- Longer follow-up revealed harm in that setting.
- primary_references
- Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738
L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 338–344
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Same randomized trial; prespecified secondary follow-up. · source_derived_draft · unverified_draft
## l-carnitine-alc-neuropathy-harm Longer follow-up revealed harm in that setting. At 24 weeks in the same taxane trial, the acetyl-L-carnitine arm had worse neuropathy scores and more severe neurotoxicity than placebo. Model: Same randomized trial; prespecified secondary follow-up. Limitations: Not a demonstrated molecular explanation of the harm; keep the clinical outcome visible. Evidence access: Primary abstract Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738
Complete structured claim and evidenceIn a 409-patient randomized trial during adjuvant taxane chemotherapy, acetyl-L-carnitine did not significantly improve the primary 12-week neuropathy endpoint.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Women with breast cancer; 3 g/day acetyl-L-carnitine versus placebo.
- limitations
- A finding for this derivative and treatment context, not every carnitine use.
- nutrient_topic
- L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
- plain_language
- A plausible nerve-protection idea failed its main clinical test.
- primary_references
- Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738
L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 330–336
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Women with breast cancer; 3 g/day acetyl-L-carnitine versus placebo. · source_derived_draft · unverified_draft
## l-carnitine-alc-neuropathy-null A plausible nerve-protection idea failed its main clinical test. In a 409-patient randomized trial during adjuvant taxane chemotherapy, acetyl-L-carnitine did not significantly improve the primary 12-week neuropathy endpoint. Model: Women with breast cancer; 3 g/day acetyl-L-carnitine versus placebo. Limitations: A finding for this derivative and treatment context, not every carnitine use. Evidence access: Primary abstract Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.